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Background: The long term outcome of the unrestricted use of new generation everolimus eluting stents (EES) in STEMI as compared to first 
generation sirolimus eluting stent (SES) is unknown. 
Methods: Patients treated for STEMI in two centres (n=2465) with SES (2002-2006) and EES implantation (2006-2009) were followed up. 
Propensity score was used to compare 875 matched pairs. The primary endpoint was the 3-year rate of MACE, a composite of death, target vessel 
revascularisation (TVR) and repeat myocardial infarction (MI).
Results: Follow-up was achieved in 97.8%. Baseline clinical characteristics were similar between the matched groups. MACE occurred with similar 
frequency in patients treated with EES (16.7%) and SES (20.5%, HR 0.86 (0.68-1.08), p=0.19). There was no difference in cardiac death or MI 
between the two groups (10.4% v. 11.7%, HR 0.96 (0.72-1.29), p=0.79. TLR occurred less frequently in the EES (4.7%) as compared to the SES 
group (7.4%) HR, 0.54 (0.34-0.85), p<0.01), and the reduction in TLR was maintained beyond one year (EES 1.8% vs 3.3%, 0.52 (0.24-1.10), p 
=0.09). Definite ST tended to be less frequent in EES than SES (2.2% v. 4.0%, HR 0.55 (0.30-1.02), p=0.06), particularly very late ST (0.83% v. 2.2% 
HR 0.34 (0.11-1.0), p=0.05).
Conclusion: In unselected STEMI patients overall clinical outcomes appear similar with EES and SES. However, there is an early and late benefit 
for EES in terms of repeat revascularization of the target lesion and stent thrombosis.
